Abbott Laboratories Stock Draws Bullish Targets Ahead Of Earnings

Abbott Laboratories stocks have been trading up by 12.53 percent after strong earnings and robust medical-device demand boosted optimism.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading ABT

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways For ABT Traders

Wall Street is leaning bullish as Baird starts coverage on Abbott Laboratories with an Outperform rating and a $121 target, pointing to mid‑single‑digit sales growth and stronger earnings through 2028.
Citi’s sum‑of‑the‑parts work on ABT pegs fair value at $99–$104 versus recent levels in the high‑$80s to low‑$90s, tied to easing headwinds and a fresh product cycle.
A global ALZpath licensing deal gives Abbott Laboratories a shot at a scalable blood test for Alzheimer’s disease on its Alinity systems, extending the diagnostics growth story.
The U.S. Department of Justice closed its long baby‑formula probe without criminal charges for ABT, shifting the focus to a civil settlement over federal nutrition‑program funds.
Evercore ISI trimmed its ABT target to $112 from $120 but kept an Outperform rating, signaling healthy MedTech demand as Q2 2026 results on 2026/07/16 approach.

Quick Financial Overview

ABT has been grinding higher on the chart, and the numbers back up why big funds still pay attention. Over the last couple of weeks, Abbott Laboratories has bounced from the high‑$80s to more than $100, with the latest close near $100.49 after a strong intraday surge from a $95.29 open. That’s a big range for a mega‑cap, and traders should respect that volatility.

Under the hood, ABT is a high‑margin machine. Gross margin sits around 56%, while EBIT margin is just over 19%. That tells traders Abbott Laboratories turns more than half of every sales dollar into gross profit and keeps a solid slice after operating costs. Annual revenue runs near $44.3B with steady low‑single‑digit growth, not a hyper‑growth story but a durable one.

More Breaking News

Valuation is not cheap, with a P/E near 25 and price‑to‑sales around 3.5. ABT is getting a quality premium. The balance sheet looks solid: debt‑to‑equity about 0.65, interest coverage above 22 times, and current ratio around 1.4. Cash flow from operations of roughly $1.3B last quarter easily covers capital spending and a cash dividend rate of about $2.52 per share. For traders, ABT acts like a steady compounder that can still put up tradable swings around catalysts.

Why Traders Are Watching ABT Now

This is one of those stretches where news and price action line up and give traders real levels to trade. On the bullish side, Baird just initiated ABT with an Outperform and a $121 price target, well above recent prices and even above the roughly $116 Street average. They are modeling 6%–8% annual sales growth and low double‑digit earnings growth powered by new products and synergies with Exact Sciences into 2027–2028. For ABT traders, that’s the Street effectively saying, “We see a multi‑year runway, not just a one‑quarter pop.”

Citi adds another layer, valuing Abbott Laboratories at $99–$104 per share using a sum‑of‑the‑parts approach. With ABT having traded around the high‑$80s to low‑$90s recently, Citi’s work implies clear double‑digit upside as COVID and macro headwinds fade and the next product cycle takes over. That gives traders a defined range to watch on the swing‑trade side.

On the catalyst front, ABT just locked in a global licensing deal with ALZpath for the pTau217 antibody to build a blood‑based Alzheimer’s diagnostics test on its Alinity ci‑series analyzers. This does not flip revenue overnight, but it plugs high‑value content into a massive installed base. If that assay scales, it can be a quiet margin booster across the Abbott Laboratories diagnostics portfolio.

At the same time, a big overhang is easing. The U.S. Department of Justice closed its years‑long probe into ABT’s baby‑formula operations without criminal charges, pivoting to a civil False Claims Act settlement focused on recouping nutrition‑program funds. Interestingly, ABT shares actually dipped about 1.3% on headlines that no charges were coming, a sign traders still worry about civil penalties and brand damage. That kind of disconnect often creates tradable volatility when new headlines hit.

Layer on top a possible policy tailwind: Abbott Laboratories, as a structural heart and cardiovascular device player, is expected to benefit from proposed CMS expansion of TAVR coverage, which already nudged ABT slightly higher premarket. It’s not a thesis on its own, but it supports the broader MedTech growth story heading into Q2 earnings on 2026/07/16.

Conclusion

For active traders, ABT is not a meme rocket, but it is a big‑liquid name where fundamentals, sentiment, and catalysts are all in motion at once. Abbott Laboratories shows strong margins, solid returns on equity, and enough balance‑sheet flexibility to keep funding R&D, deals like ALZpath, and a growing dividend. Yet the stock isn’t free; the 25x earnings multiple assumes Abbott keeps executing and that controversies like baby formula stay contained to manageable civil outcomes.

On the tape, ABT just ripped from the high‑$80s to above $100 in a single session, with intraday action showing a clean trend from the low‑$90s in premarket to over $101 after the open. That tells you momentum traders are already swarming around the story. Into the 2026/07/16 Q2 print, expect every line in the report — procedure volumes, diagnostics growth, commentary on formula, and any hints on the Alzheimer’s test — to be weighed against those bullish price targets from Baird, Citi, and Evercore ISI.

The key is to treat Abbott Laboratories like any other ticker: a trading vehicle, not a story you fall in love with. As Tim Sykes likes to say, “Discipline and risk management matter far more than any hot stock tip.” That aligns with the mentality many short‑term traders bring to names like ABT: you plan scenarios ahead of time, define your risk, and let the price action confirm or deny your thesis. As Tim Bohen, lead trainer with StocksToTrade says, “Preparation is half the trade. By the time the bell rings, my decisions are nearly made.”. For ABT, that means mapping your levels, respecting the volatility around headlines, and cutting losses fast if the thesis breaks, while using the strong institutional backdrop as context — not a guarantee.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!